ProCE Banner Activity


Optimizing Management of Patients With Cardiometabolic and Renal Disease: A Case-Based Multidisciplinary Discussion

PCE On Demand Live Presentation

This on-demand webcast features expert faculty who review the most recent guideline recommendations and clinical trial evidence on the role of sodium-glucose cotransporter 2 (SGLT2) inhibitors in cardiometabolic and renal diseases, including diabetes, heart failure, and chronic kidney disease.

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurse Practitioners: 1.00 Nursing contact hours, includes 1.00 hour of pharmacotherapy credit

Released: January 31, 2023

Expiration: January 30, 2024

No longer available for credit.



Jennifer B. Green

Jennifer B. Green, MD

Professor of Medicine
Division of Endocrinology
Department of Medicine
Duke Clinical Research Institute
Duke University Medical Center
Durham, North Carolina

Viet Le

Viet Le, DMSc, PA-C, FACC, FAHA, HF-Cert

Associate Professor of Research, Preventive Cardiology PA
Intermountain Heart and Vascular Clinical Program
Intermountain Health, Canyons Region
Salt Lake City, Utah

Laura Ross

Laura Ross, PA-C, MPAS, CLS, DipACLM, AACC

Director, Heart Disease Prevention and Lipid Clinic
Park Nicollet Heart and Vascular Center
St Louis Park, Minnesota

Matthew Weir

Matthew Weir, MD

Professor and Director
Division of Nephrology
Department of Medicine
University of Maryland School of Medicine
Baltimore, Maryland

Provided by

ProCE Banner


This activity is supported by an educational grant from

Boehringer Ingelheim Pharmaceuticals, Inc.


Academy of Physician Associates in Cardiology

ProCE Banner

Target Audience

NPs and PAs who care for patients with cardiovascular diseases.

Learning Objectives

After completing this activity, participants should be better able to:

  • Evaluate the clinical evidence for SGLT2 inhibitors beyond glycemic control

  • Differentiate among the SGLT2 inhibitors when selecting therapy for individual patients with diabetes, heart failure, and chronic kidney disease

  • Integrate SGLT2 inhibitors into treatment of appropriate patients according to evidence-based guidelines and patient-specific factors


All faculty and planners participating in continuing education activities sponsored by Partners for Advancing Clinical Education (PACE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PACE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Jennifer B. Green MD: consultant/advisor/speaker: Anji, AstraZeneca, Bayer, Boehringer Ingelheim/Lilly, Novo Nordisk, Pfizer, Sanofi/Lexicon, Valo, Vertex; researcher: Boehringer Ingelheim/Lilly, Merck, Roche.

Viet Le, MPAS, PA-C: researcher (paid to institution): Amarin, Lilly, Milestone, Novartis.

Laura Ross, PA-C, has no relevant financial relationships to disclose.

Matthew Weir, MD: advisor: Akebia, AstraZeneca, Bayer, Boehringer Ingelheim, GSK, Janssen, Merck, Novo Nordisk, Vifor.

The planners and content peer reviewers from Partners for Advancing Clinical Education and Practicing Clinicians Exchange do not have any relevant financial relationships to disclose.

Instructions for Credit

Learners wishing to earn CE/CME credit must:

  1. View the content in its entirety
  2. Relate the content material to the learning objectives
  3. Complete evaluation form

The estimated time to complete this activity is 1.00 hour.


This program has been made available online.


The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange, Partners for Advancing Clinical Education, or any educational supporter.


Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and the Academy of Physician Associates in Cardiology (APAC). Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.


ANCC Credit Designation
Nursing contact hours: 1.00, which includes 1.00 hours of pharmacology credit


AAPA Credit Designation
Joint AccreditationPartners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid until January 30, 2024. PAs should only claim credit commensurate with the extent of their participation.


IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.